Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266524 | 0.88 | HTR2C (0.47) | PRMT5HTR2CHTR2AHTR1AKDM4E | |
| SCHEMBL906142 | 0.86 | HTR2C (0.63) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL3266333 | 0.83 | HTR2C (0.59) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL11603074 | 0.78 | HTR1A (0.50) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL3267269 | 0.77 | TAAR1 (0.54) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL3267745 | 0.76 | ACHE (0.58) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL27534548 | 0.74 | PIM2 (0.48) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL906114 | 0.74 | HTR2C (0.74) | PRMT5HTR2CHTR2AHTR1AKDM4E | |
| Hydrochloric Acid SCHEMBL11605186 | 0.73 | HTR2C (0.57) | HTR2CHTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL29800737 | 0.72 | ALDH1A1 (0.45) | ALDH1A1CYP3A4HSD17B10MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | PRMT5 857/4885HTR2C 1/4885HTR2A 6/4885 |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | PRMT5 1733/4885HTR2C 4/4885HTR2A 1/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | PRMT5 1733/4885HTR2C 4/4885HTR2A 1/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | PRMT5 857/4885HTR2C 1/4885HTR2A 6/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | PRMT5 857/4885HTR2C 1/4885HTR2A 6/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | PRMT5 1742/4885HTR2C 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.